Canadian Sec - Delayed Quote CAD

Diagnamed Holdings Corp. (DMED.CN)

0.0250

-0.0050

(-16.67%)

At close: May 1 at 1:12:27 PM EDT

DiagnaMed Announces Closing of LIFE Offering

Toronto, Ontario--(Newsfile Corp. - April 14, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce that it has closed its previously announced private placement by issuing 13,250,333 units of the Company at an issue price of $0.03 per ...

Newsfile 17 days ago

DGNMF
Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that further to its press release dated March 3, 2025, it has entered into an asset purchase agreement (the “Agreement”) dated March 31, 2025 with DiagnaMed Holdings Corp. (CSE:

GlobeNewswire 30 days ago

DGNMF

RVVTF
Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for infectious diseases, rare disorders, and medical countermeasures, is pleased to announce that it has entered into a non-binding letter of intent (the “LOI”), dated February 28, 2025, to acquire the full rights to DiagnaMed Holdings Corp.’s (CSE: DMED) (OTCQB: DGNMF)

GlobeNewswire last month

RVVTF

DGNMF
DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis

Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, today announced in a significant advancement for rare disease research, the Company has been granted Orphan Drug Designation (ODD) for molecular hydrogen in the treatment of amyotrophic lateral sclerosis (ALS) by the U.S. Food and Drug Administration

Newsfile last month

DGNMF
DiagnaMed Announces LIFE Offering of up to $510,000

Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed" or the "Company"), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce that it is arranging a private placement of a minimum of $350,000 and a maximum of $510,000 of units (each, a "Unit"), at a price of $0.03 per Unit; (the "Offering"). The Offering is being led by ...

Newsfile 2 months ago

DGNMF
DiagnaMed To Support Quebec's Hydrogen Ambitions Through its Collaboration with QIMC

Toronto, Ontario--(Newsfile Corp. - February 27, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce its support of Québec Innovative Materials Corp. (CSE: QIMC) (FSE: 7FJ) (OTCQB: QIMCF) ("QIMC") efforts to establish hydrogen as a primary energy source in Quebec, aligning with the Province's mandate to reduce emissions by

Newsfile 2 months ago

DGNMF
DiagnaMed Advances Hydrogen Energy Technology Innovation

TORONTO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed”, “DMED”, or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of cutting-edge technology solutions for the hydrogen and life sciences industries, is pleased to announce significant progress in the commercialization of its proprietary electromagnetic heating technology for hydrogen production. Developed by Dr. Qingwang Yuan of the HOPE Group at Texas Tech University, this groundbreaking innovation enables

GlobeNewswire 2 months ago

DGNMF
DiagnaMed and TerraVent Announce Strategic Collaboration for Next-Generation Clean Hydrogen Production

TORONTO, Jan. 22, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading provider of innovative technology solutions for the cleantech and life sciences industries, is proud to announce a strategic collaboration with TerraVent Environmental Inc. (“TerraVent”). This partnership will advance the evaluation and integration of two ground-breaking hydrogen production technologies with TerraVent’s proprietary Heatwave® electromagnetic the

GlobeNewswire 3 months ago

DGNMF
DiagnaMed Announces Resignation of Director and Grant of Stock Options

TORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF) announces that Elyssia Patterson has resigned from the board. The Company also announces that it has granted an aggregate of 1,000,000 stock options (“Options”) to consultants at a price of $0.05 per common share, expiring five years from the date of grant and vest one-fourth increments with the first batch being released on the three-month anniversary and the remaining t

GlobeNewswire 3 months ago

DGNMF
DiagnaMed and QIMC to Advance Hydrogen Production Technology at the Ville Marie Clean Natural Renewable Hydrogen Project

A Strategic collaboration to Accelerate Clean Natural Hydrogen InnovationTORONTO, Jan. 08, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading innovator in hydrogen production technologies and artificial intelligence (AI) applications, is thrilled to announce a strategic collaboration with Québec Innovative Materials Corp. (CSE: QIMC, FSE: 7FJ, OTCQB: QIMCF) (“QIMC”). This partnership will deploy DiagnaMed’s pioneering technology

GlobeNewswire 3 months ago

DGNMF
DiagnaMed Partners with Texas Tech University to Pioneer Hydrogen Innovation

TORONTO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a leading innovator in hydrogen-producing technologies and artificial intelligence (AI) medical applications, proudly announces it has entered into a limited license and option agreement with the Texas Tech University System to commercialize a ground-breaking technology (WO2023044149A1) that produces hydrogen directly from petroleum reservoirs and natural hydrogen fields

GlobeNewswire 3 months ago

DGNMF
DiagnaMed and EIREX Collaborate to Develop and Commercialize Novel Modular Technology Producing Hydrogen from Water

Advancing hydrogen for medical and industrial usesTORONTO, Nov. 14, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI diagnostics, is pleased to announce it has entered into a collaboration agreement with EIREX, a hydrogen technology company, for the development and commercialization of EIREX’s novel modular carbon-free technology that extracts hydrogen from water and overcomes

GlobeNewswire 5 months ago

DGNMF
DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement

TORONTO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI diagnostics, announces that it has granted an aggregate of 4,500,000 stock options ("Options") to its directors, officers and consultants at a price of $0.05 per common share, expiring five years from the date of grant and vest one-fourth increments with the first batch being released on the three-month anniver

GlobeNewswire 5 months ago

DGNMF
DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen

Advancing molecular hydrogen for neurological and mental health disorders Expects its molecular hydrogen product to be ready for use in December 2024 TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on molecular hydrogen and AI diagnostics for brain health, today announced that it has filed a provisional patent application with the U.S. Patent and Trademark Office outlining pharmaceutica

GlobeNewswire 5 months ago

DGNMF
DiagnaMed Advancing the Medical Potential of Hydrogen

Focusing on novel molecular hydrogen therapies for brain healthTORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on brain health, announces its strategic initiative in advancing therapies that unlock the medical potential of molecular hydrogen for brain health. Hydrogen is well-known for its industrial use as a pollution-free fuel. The global hydrogen generation market size was estimated

GlobeNewswire 5 months ago

DGNMF
DiagnaMed Expands with Drug and Clinical Research AI Platform

Leveraging proprietary EEG data from previous and future research studies with BRAIN AGE® Brain Health AI Accelerating clinical trial development and discovering potential novel treatments for neurological, psychiatric and infectious diseases TORONTO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces it is expanding the use of its novel BRAIN AGE® Brain

GlobeNewswire 8 months ago

DGNMF
DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function

TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is offering its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”) as a clinical tool for investigating the impact of weight loss drugs, such as Semaglutide, on brain function. In a recently published study, Semaglutide, a GLP-1 receptor agonist that has been approved by the FDA and is currently mark

GlobeNewswire 8 months ago

DGNMF
DiagnaMed Cancels Previously Announced Private Placement

TORONTO, July 03, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, announces it has cancelled the private placement Offering announced on May 15, 2024. The Company is evaluating certain strategic initiatives complementary to the BRAIN AGE® Brain Health AI Platform and anticipates providing additional updates within this quarter. About DiagnaMed DiagnaMed Holdings Corp. (C

GlobeNewswire 9 months ago

DGNMF
DiagnaMed Announces LIFE Offering of up to $650,000

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is pleased to announce that it is arranging a private placement of a minimum of $400,000 and a maximum of $650,000 of units (each, a “Unit”), at a price of $0.04 per Unit; (the “Offering”). The Offering is being led by EMD Financial Inc. Each Unit will be comprised of one common share (“Common Share”) in th

GlobeNewswire 11 months ago

DGNMF
DiagnaMed’s BRAIN AGE® Brain Health AI Platform Targeting Multi-Billion Digital Brain Health Market

TORONTO, May 15, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company focused on brain health using AI, is commercializing its novel BRAIN AGE® Brain Health AI Platform (“BRAIN AGE®”), a world-first consumer brain health and wellness AI solution that estimates brain age and provides a brain health score, targeting the global digital brain health market projected to be USD 405.53 billion by 2031.1 Fabio Chiane

GlobeNewswire 11 months ago

DGNMF

Performance Overview

Return	DMED.CN	S&P/TSX Composite index (^GSPTSE)
YTD	--	+0.71%
1-Year	-37.50%	+14.11%
3-Year	-75.00%	+19.43%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Diagnamed Holdings Corp. (DMED.CN)

DiagnaMed Announces Closing of LIFE Offering

Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program

Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program

DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis

DiagnaMed Announces LIFE Offering of up to $510,000

DiagnaMed To Support Quebec's Hydrogen Ambitions Through its Collaboration with QIMC

DiagnaMed Advances Hydrogen Energy Technology Innovation

DiagnaMed and TerraVent Announce Strategic Collaboration for Next-Generation Clean Hydrogen Production

DiagnaMed Announces Resignation of Director and Grant of Stock Options

DiagnaMed and QIMC to Advance Hydrogen Production Technology at the Ville Marie Clean Natural Renewable Hydrogen Project

DiagnaMed Partners with Texas Tech University to Pioneer Hydrogen Innovation

DiagnaMed and EIREX Collaborate to Develop and Commercialize Novel Modular Technology Producing Hydrogen from Water

DiagnaMed Announces Stock Option Grants and Shares for Debt Settlement

DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen

DiagnaMed Advancing the Medical Potential of Hydrogen

DiagnaMed Expands with Drug and Clinical Research AI Platform

DiagnaMed Offering its Brain Health AI Platform for Investigating Weight Loss Drugs, such as Semaglutide (GLP-1), on Brain Function

DiagnaMed Cancels Previously Announced Private Placement

DiagnaMed Announces LIFE Offering of up to $650,000

DiagnaMed’s BRAIN AGE® Brain Health AI Platform Targeting Multi-Billion Digital Brain Health Market

Performance Overview